J P M O R G A N North America Equity Research 26 June 2026 ACADIA Pharmaceuticals Quick Take on Positive CHMP Opinion for Daybu Following Re-Examination Procedure We are positively surprised to see that the European Medical Agency (EMA)'s CHMP has adopted a positive opinion following a re-examination procedure, recommending marketing authorization for Daybu (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. The European Co ...